# MoonLake Immunotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moonlake-immunotherapeutics

- Industry: Biotechnology
- Headquarters: Zug, Switzerland
- Website: www.moonlaketx.com
- Latest round: Series A (May 3, 2021)
- Investors on record: 2

## About

Founded in 2021 and headquartered in Zug, Switzerland, MoonLake Immunotherapeutics AG focuses on developing innovative therapeutic solutions for inflammatory diseases through its lead product, Sonelokimab.MoonLake Immunotherapeutics AG specializes in creating advanced treatments targeting inflammatory conditions. The company was founded in 2021 by Arnout Van Amstel, Jorge Da Silva, and Kristian Reich, with Jorge Da Silva currently serving as CEO. The firm has successfully completed three deals, including a Private Placement/Follow on in June 2023, raising USD 400.00 mn, bringing its total funding to USD 400.00 mn. Moonlake Immunotherapeutics specializes in the development of innovative therapeutic solutions targeting inflammatory diseases. Their core product, Sonelokimab, is a Nanobody® designed to address conditions such as hidradenitis suppurativa, psoriatic arthritis, psoriasis, and ankylosing spondylitis. These treatments aim to alleviate the severe impact of these long-term conditions on patients' quality of life. Moonlake actively sponsors and conducts clinical trials globally, particularly focusing on Phase 2 and Phase 3 programs for Sonelokimab, which are being rolled out in various regions, including Europe and North America. The company targets both healthcare providers and patients suffering from these debilitating inflammatory conditions, aiming to meet significant unmet medical needs.Moonlake Immunotherapeutics generates revenue through partnerships and collaborations with healthcare institutions and research organizations, focusing on clinical trial advancements and product development. The company's business model involves direct agreements with healthcare providers for the distribution of Sonelokimab once approved for commercial use. Revenue is primarily linked to the successful commercialization and adoption of Sonelokimab in the treatment of inflammatory diseases, while the EBITDA for the most recent year, 2023, is reported at USD -54,109,938.In June 2023, MoonLake Immunotherapeutics AG raised USD 400 mn in a private placement, selling 8 million shares at USD 50 per share. The company plans to utilize this funding to advance the development of Sonelokimab and support general corporate purposes. Future growth strategies may include introducing new products and expanding into markets across Europe and North America, aligning with ongoing clinical trials and regulatory efforts.

## Funding rounds

- Series A, May 3, 2021 — BVF Partners, Merck KGaA

## Investors

- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A
- Merck KGaA — Series A